My watch list
my.bionity.com  
Login  

Neuromed Pharmaceuticals and Merck & Co., Inc. Announce Agreement for Novel N-type Calcium Channel Compounds

21-Mar-2006

Neuromed Pharmaceuticals Ltd. and Merck & Co., Inc. announced that they have signed a research collaboration and license agreement to research, develop and commercialize novel compounds for the treatment of pain and other neurological disorders, including Neuromed's lead compound, NMED-160, which is currently in Phase II development for the treatment of pain.

Under the terms of the agreement, Neuromed grants Merck an exclusive worldwide license to research, develop and commercialize NMED-160 and other compounds that selectively target the N-type calcium channel. Merck will make a $25 million initial cash payment to Neuromed. Neuromed will also receive research funding from Merck for two years as part of the collaborative research program, including the option to renew for an additional two years. Merck is responsible for all development costs and activities.

The successful development and launch of NMED-160 for an initial single indication on a worldwide basis would trigger milestone payments totaling $202 million. Milestones could increase to approximately $450 million if a further indication for NMED-160 is developed and approved and a further compound is developed and approved for two indications. Neuromed would also receive royalties on worldwide sales of NMED-160 and any additional compounds developed under this agreement. Additional milestone payments would be payable should further compounds be developed. Further financial terms were not disclosed.

Facts, background information, dossiers
  • Merck
  • Neuromed Pharmaceuticals
  • milestone payments
  • neurological disorders
  • milestones
  • license agreements
More about Merck Sharp & Dohme
  • News

    Merck and Pfizer Collaborate with Corning to Modernize Pharmaceutical Glass Packaging

    Merck & Co., Pfizer and Corning Incorporated announced collaborations that have enabled the modernization of pharmaceutical packaging with the introduction of Corning Valor™ Glass. This revolutionary pharmaceutical glass packaging solution enhances the storage and delivery of today’s drug f ... more

    Merck prices EUR 1.0 billion debt offering

    Merck & Co., Inc., known as MSD outside the United States and Canada, priced today a EUR 1.0 billion public offering of two series of Euro-denominated senior unsecured notes (collectively, the “New Notes”). Based on Oct. 21, 2016, closing exchange rates the EUR 1.0 billion equates to approx ... more

    Major pharma companies sign up to groundbreaking Parkinson's consortium

    Seven of the world's largest pharmaceutical companies have signed up to a groundbreaking consortium aimed at accelerating the development of safe and effective therapies for Parkinson's. The Critical Path for Parkinson's consortium will bring together leading academics; industry members Abb ... more

  • Companies

    Merck Sharp & Dohme Limited

    We are inspired by the difference we can make in the lives of people around the world through the innovative medicines, vaccines, and consumer health and animal products we discover and produce. Our products cover a broad range of areas, including heart and respiratory health, infectious di ... more

More about Neuromed Pharmaceuticals
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE